Pipeline Therapeutics has reported positive results from the Phase I clinical trial in healthy subjects assessing PIPE-307, which is being developed to potentially treat multiple sclerosis (MS).

A lead programme of the company for myelin restoration, PIPE-307 is an oral, selective antagonist of the muscarinic M1 receptor.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The double-blind, randomised, placebo-controlled trial analysed the safety and tolerability of PIPE-307 in 70 healthy adult subjects enrolled at a single site in Australia.

It was carried out in three parts: a single ascending dose (SAD) study, a multiple ascending dose (MAD) study and a selected SAD arm to assess the impact of food on PIPE-307 bioavailability. 

Assessing the safety and tolerability of PIPE-307 was the trial’s primary endpoint while the secondary endpoint analysed the therapy’s effect on pharmacokinetics. 

According to the trial findings, the oral therapy demonstrated to possess favourable safety and pharmacokinetic (PK) profile and met the primary and secondary endpoints. 

Furthermore, PIPE-307 was found to have pharmacokinetic (PK) data in line with preclinical modelling and was well tolerated across all tested doses. 

The trial included various neuropsychological assessments, including tests for psychomotor, attention, learning, and executive function. 

No substantial PK or dose associated effects on cognitive function were observed.

Pipeline Therapeutics Clinical Development chief medical officer and senior vice-president Stephen Huhn said: “The results of the single- and multiple-ascending dose cohorts from the completed Phase I study demonstrate a favourable safety and PK profile, and we are pleased to have met our primary and secondary endpoints in this study. 

“These encouraging Phase I results give us great confidence to advance PIPE-307 into clinical studies with MS patients as soon as possible.”